Company Filing History:
2 out of 7 
2 out of 932 
Years Active: 2008
Title: Lakhdar Arab: Innovator in Hematopoietic Cell Treatments
Introduction
Lakhdar Arab is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of hematopoietic cell treatments, holding two patents that focus on innovative therapeutic approaches.
Latest Patents
His latest patents include the development of CXCR4 antagonist treatment of hematopoietic cells. This invention outlines the use of CXCR4 antagonists to treat hematopoietic cells, such as progenitor or stem cells, promoting cellular multiplication, self-renewal, proliferation, or expansion. Additionally, he has patented CXC chemokine receptor 4 agonist peptides, which may be used to reduce the rate of hematopoietic cell multiplication. The methods described in this patent involve administering an effective amount of a CXCR4 agonist to hematopoietic stem and progenitor cells, either in vitro or in vivo, to aid patients requiring bone marrow or peripheral blood stem cell transplantation.
Career Highlights
Lakhdar Arab has worked with Chemokine Therapeutics Corporation and the University of British Columbia, where he has furthered his research and development in the field of hematopoietic cell therapies.
Collaborations
He has collaborated with notable coworkers, including Christopher R Tudan and Ahmed Merzouk, contributing to advancements in his field.
Conclusion
Lakhdar Arab's innovative work in hematopoietic cell treatments showcases his dedication to improving therapeutic options for patients. His patents reflect a commitment to advancing medical science and enhancing patient care.